Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer's disease: results from the DELCODE study.
Alzheimer’s disease
Biomarker
Blood-based
Cognition
Inflammation
Structural MRI
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
12 01 2023
12 01 2023
Historique:
received:
31
05
2022
accepted:
06
11
2022
entrez:
11
1
2023
pubmed:
12
1
2023
medline:
14
1
2023
Statut:
epublish
Résumé
Neuroinflammation constitutes a pathological hallmark of Alzheimer's disease (AD). Still, it remains unresolved if peripheral inflammatory markers can be utilized for research purposes similar to blood-based beta-amyloid and neurodegeneration measures. We investigated experimental inflammation markers in serum and analyzed interrelations towards AD pathology features in a cohort with a focus on at-risk stages of AD. Data of 74 healthy controls (HC), 99 subjective cognitive decline (SCD), 75 mild cognitive impairment (MCI), 23 AD relatives, and 38 AD subjects were obtained from the DELCODE cohort. A panel of 20 serum biomarkers was determined using immunoassays. Analyses were adjusted for age, sex, APOE status, and body mass index and included correlations between serum and CSF marker levels and AD biomarker levels. Group-wise comparisons were based on screening diagnosis and routine AD biomarker-based schematics. Structural imaging data were combined into composite scores representing Braak stage regions and related to serum biomarker levels. The Preclinical Alzheimer's Cognitive Composite (PACC5) score was used to test for associations between the biomarkers and cognitive performance. Each experimental marker displayed an individual profile of interrelations to AD biomarkers, imaging, or cognition features. Serum-soluble AXL (sAXL), IL-6, and YKL-40 showed the most striking associations. Soluble AXL was significantly elevated in AD subjects with pathological CSF beta-amyloid/tau profile and negatively related to structural imaging and cognitive function. Serum IL-6 was negatively correlated to structural measures of Braak regions, without associations to corresponding IL-6 CSF levels or other AD features. Serum YKL-40 correlated most consistently to CSF AD biomarker profiles and showed the strongest negative relations to structure, but none to cognitive outcomes. Serum sAXL, IL-6, and YKL-40 relate to different AD features, including the degree of neuropathology and cognitive functioning. This may suggest that peripheral blood signatures correspond to specific stages of the disease. As serum markers did not reflect the corresponding CSF protein levels, our data highlight the need to interpret serum inflammatory markers depending on the respective protein's specific biology and cellular origin. These marker-specific differences will have to be considered to further define and interpret blood-based inflammatory profiles for AD research.
Sections du résumé
BACKGROUND
Neuroinflammation constitutes a pathological hallmark of Alzheimer's disease (AD). Still, it remains unresolved if peripheral inflammatory markers can be utilized for research purposes similar to blood-based beta-amyloid and neurodegeneration measures. We investigated experimental inflammation markers in serum and analyzed interrelations towards AD pathology features in a cohort with a focus on at-risk stages of AD.
METHODS
Data of 74 healthy controls (HC), 99 subjective cognitive decline (SCD), 75 mild cognitive impairment (MCI), 23 AD relatives, and 38 AD subjects were obtained from the DELCODE cohort. A panel of 20 serum biomarkers was determined using immunoassays. Analyses were adjusted for age, sex, APOE status, and body mass index and included correlations between serum and CSF marker levels and AD biomarker levels. Group-wise comparisons were based on screening diagnosis and routine AD biomarker-based schematics. Structural imaging data were combined into composite scores representing Braak stage regions and related to serum biomarker levels. The Preclinical Alzheimer's Cognitive Composite (PACC5) score was used to test for associations between the biomarkers and cognitive performance.
RESULTS
Each experimental marker displayed an individual profile of interrelations to AD biomarkers, imaging, or cognition features. Serum-soluble AXL (sAXL), IL-6, and YKL-40 showed the most striking associations. Soluble AXL was significantly elevated in AD subjects with pathological CSF beta-amyloid/tau profile and negatively related to structural imaging and cognitive function. Serum IL-6 was negatively correlated to structural measures of Braak regions, without associations to corresponding IL-6 CSF levels or other AD features. Serum YKL-40 correlated most consistently to CSF AD biomarker profiles and showed the strongest negative relations to structure, but none to cognitive outcomes.
CONCLUSIONS
Serum sAXL, IL-6, and YKL-40 relate to different AD features, including the degree of neuropathology and cognitive functioning. This may suggest that peripheral blood signatures correspond to specific stages of the disease. As serum markers did not reflect the corresponding CSF protein levels, our data highlight the need to interpret serum inflammatory markers depending on the respective protein's specific biology and cellular origin. These marker-specific differences will have to be considered to further define and interpret blood-based inflammatory profiles for AD research.
Identifiants
pubmed: 36631909
doi: 10.1186/s13195-022-01118-0
pii: 10.1186/s13195-022-01118-0
pmc: PMC9835320
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
Chitinase-3-Like Protein 1
0
Interleukin-6
0
tau Proteins
0
AXL protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13Informations de copyright
© 2023. The Author(s).
Références
Pharmacol Ther. 2018 Aug;188:97-117
pubmed: 29514053
Science. 2019 Dec 20;366(6472):
pubmed: 31857451
Neurology. 2007 Mar 27;68(13):1032-8
pubmed: 17389308
Alzheimers Dement. 2019 Jun;15(6):776-787
pubmed: 31047856
Biomarkers. 2008 Sep;13(6):618-36
pubmed: 18830857
Int J Chron Obstruct Pulmon Dis. 2018 Jan 30;13:409-418
pubmed: 29430175
Neurosci Lett. 2018 Nov 1;686:10-16
pubmed: 30171911
Brain. 2006 Nov;129(Pt 11):3042-50
pubmed: 17071923
Brain Behav Immun. 2017 Oct;65:150-160
pubmed: 28457809
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Data Brief. 2017 Oct 16;15:648-657
pubmed: 29124088
Neuron. 2022 Mar 16;110(6):1009-1022.e4
pubmed: 34995486
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
J Alzheimers Dis. 2020;76(1):349-368
pubmed: 32474469
Brain Behav Immun. 2020 Jul;87:388-396
pubmed: 31935468
Neurobiol Aging. 2020 Dec;96:22-32
pubmed: 32920471
Front Aging Neurosci. 2020 Oct 30;12:553998
pubmed: 33192454
Alzheimers Res Ther. 2016 Oct 18;8(1):43
pubmed: 27756387
Transl Psychiatry. 2013 Aug 20;3:e293
pubmed: 23962923
J Alzheimers Dis. 2022;87(2):545-555
pubmed: 35275535
Mol Neurobiol. 2014 Oct;50(2):534-44
pubmed: 24567119
Cancers (Basel). 2016 Nov 09;8(11):
pubmed: 27834845
Biol Psychiatry. 2010 Nov 15;68(10):903-12
pubmed: 21035623
J Neuroinflammation. 2020 Oct 29;17(1):324
pubmed: 33121494
J Neurol Neurosurg Psychiatry. 2017 Oct;88(10):876-882
pubmed: 28794151
J Clin Med. 2020 Oct 27;9(11):
pubmed: 33121040
Mol Cell Proteomics. 2005 Dec;4(12):1920-32
pubmed: 16127175
Stroke. 2014 Feb;45(2):605-7
pubmed: 24399375
J Exp Med. 2020 May 4;217(5):
pubmed: 32267936
Alzheimers Dement. 2020 Feb;16(2):292-304
pubmed: 31630996
J Alzheimers Dis. 2013;33(2):323-8
pubmed: 22976070
Psychol Med. 2020 Dec;50(16):2790-2798
pubmed: 31615590
Front Aging Neurosci. 2018 Dec 11;10:409
pubmed: 30618716
Dis Markers. 2019 Sep 15;2019:2387614
pubmed: 31636733
J Am Geriatr Soc. 2016 Sep;64(9):1823-9
pubmed: 27549073
Alzheimers Dement (Amst). 2015 Mar 29;1(1):48-60
pubmed: 27239491
Lancet Neurol. 2015 Apr;14(4):388-405
pubmed: 25792098
Brain Behav Immun. 2020 Jul;87:679-688
pubmed: 32135194
Neuron. 2016 Mar 2;89(5):971-982
pubmed: 26938442
J Alzheimers Dis. 2017;60(1):273-281
pubmed: 28826184
J Alzheimers Dis. 2014;38(3):497-501
pubmed: 24002183
EMBO Mol Med. 2016 May 02;8(5):466-76
pubmed: 26941262
Alzheimers Res Ther. 2018 Feb 26;10(1):25
pubmed: 29482610
Alzheimer Dis Assoc Disord. 2020 Jan-Mar;34(1):47-53
pubmed: 31414991
Alzheimers Res Ther. 2017 Jul 28;9(1):52
pubmed: 28750675
Dis Markers. 2019 Sep 8;2019:2304931
pubmed: 31583026
Annu Rev Physiol. 2011;73:479-501
pubmed: 21054166
PLoS One. 2012;7(9):e44260
pubmed: 23028511
Eur J Neurol. 2011 Jun;18(6):865-71
pubmed: 21143341
Int Immunol. 2021 Mar 1;33(3):127-148
pubmed: 33337480
Proteome Sci. 2014 Jan 17;12(1):5
pubmed: 24433274
Cereb Cortex. 2004 Jan;14(1):11-22
pubmed: 14654453
Psychoneuroendocrinology. 2015 Jan;51:557-66
pubmed: 25465168
Curr Opin Clin Nutr Metab Care. 2014 Mar;17(2):124-9
pubmed: 24500438
J Neurochem. 2021 Jun;157(6):2210-2224
pubmed: 32894885
J Alzheimers Dis. 2016 Mar 29;52(2):561-72
pubmed: 27031486
Transl Neurosci. 2014 Mar;5(1):1-7
pubmed: 27066268
J Alzheimers Dis. 2015;49(4):1105-14
pubmed: 26599049
Exp Ther Med. 2021 Mar;21(3):263
pubmed: 33603870
Ann Neurol. 2019 Jan;85(1):47-58
pubmed: 30485483
Alzheimers Res Ther. 2017 Feb 14;9(1):8
pubmed: 28193256
J Neurol. 2008 Nov;255(11):1712-20
pubmed: 19156487
Brain Behav Immun. 2021 Jul;95:178-189
pubmed: 33737171
Am J Epidemiol. 2011 Nov 1;174(9):1077-88
pubmed: 21965187
Front Aging Neurosci. 2018 Dec 17;10:414
pubmed: 30618720
Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):194-202
pubmed: 16492905
Sci Adv. 2021 Jul 28;7(31):
pubmed: 34321199
Curr Alzheimer Res. 2018 Mar 14;15(5):493-501
pubmed: 29298649
J Alzheimers Dis. 2012;30(2):311-21
pubmed: 22426016
Sci Rep. 2018 Jul 3;8(1):10054
pubmed: 29968776
Brain Behav Immun. 2015 Aug;48:195-204
pubmed: 25882911
Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2140-2156
pubmed: 33677733
J Alzheimers Dis. 2015;43(4):1355-73
pubmed: 25159666
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Neurodegener Dis. 2007;4(5):366-75
pubmed: 17622779
J Alzheimers Dis. 2015;45(2):369-72
pubmed: 25589717
J Alzheimers Dis. 2017;56(1):25-36
pubmed: 27911318
Science. 2020 Mar 6;367(6482):
pubmed: 32139519
J Neurol Sci. 2008 Mar 15;266(1-2):20-4
pubmed: 17869272
Biol Psychiatry. 2019 Jul 15;86(2):153-162
pubmed: 31054766
Mol Brain. 2020 May 4;13(1):66
pubmed: 32366277
Alzheimer Dis Assoc Disord. 2012 Oct-Dec;26(4):329-34
pubmed: 22052466
Dis Markers. 2020 Jan 19;2020:1614627
pubmed: 32051695
J Alzheimers Dis. 2013;37(1):185-95
pubmed: 23948885
Neurology. 2016 Aug 2;87(5):539-47
pubmed: 27371494
Neurology. 2012 Mar 6;78(10):720-7
pubmed: 22357713
Curr Neuropharmacol. 2017;15(6):906-917
pubmed: 28183245
Alzheimers Res Ther. 2018 Feb 07;10(1):15
pubmed: 29415768
Alzheimers Res Ther. 2018 Sep 25;10(1):98
pubmed: 30253800
Alzheimers Dement (N Y). 2017 Nov 10;3(4):668-677
pubmed: 29264389